{
  "company": "TDOC",
  "sections": {
    "PART I": {
      "Item 1. Business": {
        "summary": "Here are the key facts from PART I - Item 1. Business section in bullet points:\n\n• Teladoc Health was founded more than 20 years ago.\n• The company completed approximately 17.3 million telehealth visits in 2024 through its business-to-business and direct-to-consumer channels.\n• As of December 31, 2024, approximately 94 million members in the United States have access to one or more of Teladoc Health's products and services."
      },
      "Item 1A. Risk Factors": {
        "summary": "Here are the key facts from the PART I - Item 1A. Risk Factors section in bullet points:\n\n• The company has a history of cumulative losses, with net losses of $1,001.2 million and $220.4 million for the years ended December 31, 2024 and 2023, respectively.\n• As of December 31, 2024, the company had an accumulated deficit of $16,229.9 million.\n• The company incurred a non-cash goodwill impairment charge of $790.0 million in the year ended December 31, 2024.\n• The company expects to continue its history of cumulative losses and may never achieve or sustain profitability."
      },
      "Item 1C. Cybersecurity": {
        "summary": "Here are the key facts from PART I - Item 1C. Cybersecurity section in bullet points:\n\n• TDOC processes and maintains sensitive data on clients and members, including PHI and PII.\n• The company has a cybersecurity program and controls as part of its enterprise risk management program to reduce the risk of exposure of information and systems.\n• TDOC leverages industry frameworks such as HIPAA, NIST Cybersecurity Framework, and HITRUST for adopting and assessing controls.\n• The company has an active HITRUST certification and SOC 2 Type II security compliance issued by external entities.\n• Controls in place include vulnerability scanning, endpoint detection capabilities, multifactor authentication, and blocking of malicious email.\n• TDOC provides annual cybersecurity awareness training for employees.\n• The company engages with an external security firm to perform regular penetration testing.\n• Critical third-party service providers are subject to risk assessment prior to engagement and periodic thereafter.\n• TDOC has a documented security incident response plan in place.\n• The audit committee of the Board maintains primary responsibility for overseeing cybersecurity risk as part of its program of regular risk management oversight."
      },
      "Item 2. Properties": {
        "summary": "Here are the key facts from PART I - Item 2. Properties section in bullet points:\n\n• The term of the lease for TDOC's corporate headquarters in Purchase, New York expires in August 2028.\n• TDOC leases additional office space in the U.S. and other foreign locations.\n• The company has reduced its footprint over the past year due to post-pandemic remote work changes.\n• TDOC intends to relocate its corporate headquarters to New York City in the second half of 2025."
      }
    },
    "PART II": {
      "Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities": {
        "summary": "Here are the key facts from PART II - Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities:\n\n• Our Common Stock trades on the New York Stock Exchange (NYSE) under the symbol \"TDOC\".\n• As of February 18, 2025, there were 84 shareholders of record of our Common Stock.\n• We have never declared or paid any cash dividends on our Common Stock and do not anticipate paying cash dividends in the foreseeable future.\n• There were no unregistered sales of equity securities which have not been previously disclosed in a quarterly report on Form 10-Q or a current report on Form 8-K during the period covered by this report.\n• We did not purchase any of our registered equity securities during the period covered by this report."
      },
      "7. Management’s Discussion and Analysis of Financial Condition and Results of Operations": {
        "summary": "Here are the key facts from PART II - 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations section:\n\n• Teladoc Health was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008.\n• The company changed its corporate name to Teladoc Health, Inc. on August 10, 2018.\n• The principal executive office is located in Purchase, New York.\n• Teladoc Health is the global leader in virtual care.\n• The company was founded with a vision of making virtual care accessible anywhere in the world on users' terms.\n• Favorable secular trends in the healthcare industry were accelerated by the COVID-19 pandemic, driving greater consumer awareness and use of virtual care."
      },
      "Item 7A. Quantitative and Qualitative Disclosures About Market Risk": {
        "summary": "Here are the key facts from PART II - Item 7A. Quantitative and Qualitative Disclosures About Market Risk section of TDOC's Annual Report:\n\n• A 1% change in interest rates would result in a change of interest income generated from TDOC's cash and cash equivalents by approximately $12.3 million over the next 12 months.\n\n• Approximately 84% of TDOC's revenues come from operations within the U.S.\n\n• TDOC has not historically utilized hedging strategies with respect to its foreign currency exchange exposure, but may begin to do so in the future.\n\n• No client represented over 10% of consolidated revenues for the years ended December 31, 2024 or 2023.\n\n• Revenue from the five largest customers accounted for 31% and 34% of total Integrated Care segment revenue for the years ended December 31, 2024 and 2023, respectively."
      },
      "Item 9A. Controls and Procedures": {
        "summary": "Here are the key facts from PART II - Item 9A. Controls and Procedures section in bullet points:\n\n• As of December 31, 2024, TDOC's management concluded that its disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by the company is recorded, processed, summarized, and reported within specified time periods.\n\n• There were no changes in TDOC's internal control over financial reporting during the three months ended December 31, 2024 that have materially affected or are reasonably likely to affect its internal control.\n\n• TDOC's management assessed the effectiveness of its internal control over financial reporting as of December 31, 2024 using the COSO framework and concluded that it maintained effective internal control at the reasonable assurance level.\n\n• Ernst & Young LLP, an independent registered public accounting firm, audited Teladoc Health, Inc.'s internal control over financial reporting as of December 31, 2024 and concluded that TDOC maintained effective internal control in all material respects."
      },
      "Other Information": {
        "summary": "Here are the key facts extracted from the PART II - Other Information section in bullet points:\n\n• The TDOC's 2023 Employment Inducement Incentive Award Plan was amended on February 27, 2025, to increase the number of shares reserved for issuance under the plan by 1,000,000 shares.\n• The amendment increased the total number of shares reserved for issuance under the 2023 Inducement Plan from 4,500,000 to 5,500,000 shares.\n• Fernando Madeira Rodrigues, TDOC's President of BetterHelp, adopted a Rule 10b5-1 trading arrangement on November 18, 2024, which was amended on November 27, 2024.\n• The Rule 10b5-1 trading plan allows for the sale of up to 36,540 shares of common stock through December 2025."
      }
    },
    "PART III": {
      "Item 10. Directors, Executive Officers and Corporate Governance": {
        "summary": "Here are the key facts from PART III - Item 10. Directors, Executive Officers and Corporate Governance section of TDOC's Annual Report:\n\n• The full text of TDOC's Code of Business Conduct and Ethics is posted on its website at www.teladochealth.com.\n• TDOC intends to disclose any amendments to its Code of Business Conduct and Ethics or waivers of its requirements on its website.\n• A copy of TDOC's insider trading policy, Exhibit 19.1, is filed as part of this Annual Report on Form 10-K for the fiscal year ended December 31, 2024.\n• TDOC complies with federal securities laws and applicable exchange listing requirements when trading in its own securities."
      }
    },
    "PART IV": {
      "Item 15. Exhibits and Financial Statement Schedules": {
        "summary": "Here are the key facts extracted from PART IV - Item 15. Exhibits and Financial Statement Schedules section in bullet points:\n\n• The consolidated financial statements for TDOC are listed in the Index to Consolidated Financial Statements and Supplemental Data filed as part of this Annual Report on Form 10-K.\n\n• Schedule II—Valuation and Qualifying Accounts lists valuation adjustments, including $0 (no specific amount provided) in \"Other\" that reflects currency translation adjustments.\n\n• The \"Other\" category primarily reflects adjustments related to the adoption of ASU 2020-06.\n\n• The \"Other\" category also includes adjustments recorded against goodwill related to the acquisition of Livongo and additional paid-in capital related to the conversion of certain convertible senior notes."
      },
      "Item 16. Form 10-K Summary": {
        "summary": "Here are the key facts extracted from PART IV - Item 16. Form 10-K Summary section in bullet points:\n\n• The registrant, Teladoc Health, Inc., has audited its consolidated financial statements for the year ended December 31, 2024.\n• The audit was conducted by an independent registered public accounting firm and expressed an unqualified opinion on the financial statements.\n• The Company changed its method of accounting for Convertible Senior Notes in 2022 due to the adoption of FASB Accounting Standards Update 2020-06.\n• The auditor's responsibility is to express an opinion on the Company's financial statements based on their audits, and they are required to be independent with respect to the Company.\n• The audit was conducted in accordance with the standards of the Public Company Accounting Oversight Board (PCAOB) and provided a reasonable basis for the opinion."
      }
    }
  },
  "metadata": {
    "parts_count": 4,
    "total_sections": 23,
    "models_used": {
      "summarization": "llama3.2",
      "embedding": "dengcao/Qwen3-Embedding-0.6B:Q8_0"
    },
    "ollama_base_url": "http://localhost:11434"
  }
}